Commentary & Deal Flow

Final terms: EUR890m E+325 at par (EUR465m upsize to refinance EUR450m 7.125% sr sec notes due 08-APR-2030 notes)

Price Talk: E+325-350, 0%, par

IPT: High 3s, par

• Issuer: Neopharmed Gentili S.p.A.
• Ticker: NEGENT
• Size: EUR890m (up from EUR425m)
• Format: 144A/Reg S; No Reg Rights
• Security: Senior Secured FRN due 2033 (7y)
• Corporate Ratings (M/S/F): B3 (positive) / B (stable) / B (stable)
• Issue Ratings (M/S/F): B3 / B / B
• Optional Redemption: NC1 (par) MWC B+50bp
• Change of Control: 101
• Day Count: ACT/365
• Denominations: 100kx1k
• Listing: Luxembourg Stock Exchange
• Law: New York
• Sole Global Coordinator and Physical Bookrunner: BNP Paribas (B&D)
• Joint Bookrunners: Banca Akros, CACIB, GS, IMI, JPM, Natixis
• UOP: refinance its EUR400m sr sec FRNs due 08-Apr-30 (callable at 100), and fund a EUR23m distribution to its parent to repay a portion of the EUR157m PIK Notes (EUR465m upsize to refinance EUR450m 7.125% sr sec notes due 08-APR-2030 notes)
• Equity Sponsors: Renaissance Partners (42.1%)/Ardian (42.1%)/Del Bono family (14.4%)
• Biz: A leading primary care pharmaceutical company in Italy that promotes a well-established and diversified portfolio of leading branded off-patent products
• HQ: Milan, Italy
• Timing: Books close 18-Jun-26 at 10:00 UKT / 11:00 CET. Pricing thereafter.

Marketing:

• Investor Call: GIC 8:30 UKT / 9:30 CET, 16-June-2026
• Q&A Sessions: 16/17-June-2026

https://dealroadshow.com/e/NEO2026 (Access Code: NEO2026)

https://evercall.co/oacc/46099 (GIC Registration)